Core Insights - The company, Eurofins, emphasizes its commitment to the Chinese market with the guiding principle of "Establishing China, Benefiting China, and Enriching the World" [1][10] - Eurofins has been actively participating in the China International Import Expo (CIIE) for four consecutive years, viewing it as a vital platform for connecting with potential partners and expanding collaboration [2][10] - The company is focusing on increasing investments in China, particularly in innovative drug development and local partnerships to enhance its product pipeline [3][5][10] Investment Strategy - Eurofins plans to deepen its exploration of early-stage innovative drug assets in China, recognizing the high value of Chinese innovation in the pharmaceutical sector [2][5] - The company has already established a collaboration project and is actively seeking local partners in nine therapeutic areas to drive commercialization in the Chinese market [3][5] Product Development - Eurofins is set to launch a new lipid-lowering combination drug in China by July 2024, further expanding its product offerings in the cardiovascular health sector [6][10] - The company has a strong historical presence in lipid management, having introduced several first-in-class products to address unmet medical needs in this area [6][7] Market Challenges - Despite high awareness of hypertension and diabetes, awareness of dyslipidemia remains low in China, with only 11.7% of adults aware of their lipid levels, leading to a significant treatment gap [7][10] - Eurofins is working to improve the accessibility of quality products through collaborations with various healthcare institutions and enhancing the capabilities of healthcare professionals [7][9] Future Outlook - The company aims to explore more collaborations in areas affecting family health, including women's health and chronic diseases, while adapting to the evolving Chinese market [10] - Eurofins is committed to leveraging the CIIE as a key platform to showcase its health solutions and contribute to the high-quality development of China's population [10]

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 你最近检测过自己的血脂吗？根据《中国成人血脂管理指南（2023年）》的数据，2018年我国18岁及以上人群血脂异常的总患病率已高达 35.6%。这包括高胆固醇血症、高甘油三酯血症、混合型高脂血症以及低高密度脂蛋白胆固醇血症。 血脂异常在早期通常没有明显症状，但实际上血管已经在悄悄受损。随着病情进展，脂肪、胆固醇等物质在血管内逐渐沉积，形成"斑块"，导 致血管逐步硬化、变窄，进而大幅提升动脉粥样硬化性心血管疾病的风险。 很多人以为高血脂只是中老年人才需要担心的健康问题。事实上，过去针对动脉粥样硬化的筛查和防控，大多也是聚焦在50岁以上胆固醇偏高 的人群。 然而，最近《自然》杂志发表的新研究提醒我们，动脉粥样硬化的预防应更早开始，年轻时就要重视血脂管理，尤其要警惕高脂饮食在儿童和 青少年中的摄入。 在这项研究中，剑桥大学心肺研究所的科学家用小鼠做实验，探索高脂饮 ...

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 血脂异常在早期通常没有明显症状，但实际上血管已经在悄悄受损。随着病情进展，脂肪、胆固醇等物质在血管内逐渐沉积，形成"斑块"，导 致血管逐步硬化、变窄，进而大幅提升动脉粥样硬化性心血管疾病的风险。 很多人以为高血脂只是中老年人才需要担心的健康问题。事实上，过去针对动脉粥样硬化的筛查和防控，大多也是聚焦在50岁以上胆固醇偏高 的人群。 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 你最近检测过自己的血脂吗？根据《中国成人血脂管理指南（2023年）》的数据，2018年我国18岁及以上人群血脂异常的总患病率已高达 35.6%。这包括高胆固醇血症、高甘油三酯血症、混合型高脂血症以及低高密度脂蛋白胆固醇血症。 然而，最近《自然》杂志发表的新研究提醒我们，动脉粥样硬化的预防应更早开始，年轻时就要重视血脂管理，尤其要警惕高脂饮食在儿童和 青少年中的摄入。 在这项研究中，剑桥大学心肺研究所的科学家用小鼠做实验，探索高脂饮 ...

Core Viewpoint - High blood lipid levels are a common chronic cardiovascular disease that is often misunderstood, leading to mismanagement of blood lipid levels and health risks [1] Misunderstandings - The belief that lower blood lipid levels are always better is incorrect; cholesterol is essential for cell membranes and hormone synthesis, and excessively low levels can lead to health issues [2] - There is a misconception that thin individuals do not have blood lipid issues; however, blood lipid levels are influenced by genetics, metabolism, diet, and exercise, not just body weight [3] - High blood lipid levels are not solely an "elderly disease"; there is a rising trend of high blood lipid cases among younger populations due to unhealthy lifestyles [4] - The idea that avoiding meat guarantees low blood lipid levels is misleading; high carbohydrate and sugary foods can also elevate blood lipid levels, and cholesterol from diet only accounts for 20% of total cholesterol [5] - Many individuals believe that the absence of symptoms means no treatment is necessary; however, high blood lipid levels can silently damage blood vessels, leading to serious health risks [6] - The assumption that a lab report without arrows indicates normal levels is flawed; individual assessments are necessary for accurate health evaluations [8] - Some patients think that taking lipid-lowering medication allows them to disregard dietary and lifestyle changes; however, medication should be complemented with healthy habits for effective management [9] - The belief that once blood lipid levels are lowered, medication can be stopped is dangerous; many patients require long-term medication to maintain healthy levels and prevent rebound effects [10]

Core Viewpoint - The increasing levels of blood lipids and the prevalence of dyslipidemia among Chinese individuals highlight the need for better management of low-density lipoprotein cholesterol (LDL-C) to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) [1][2][3] Group 1: Importance of LDL-C Management - LDL-C is identified as a major contributor to high blood lipids and a significant risk factor for ASCVD, emphasizing the importance of lowering LDL-C levels to reduce morbidity and mortality associated with cardiovascular diseases [1][2] - Experts advocate for a targeted and stratified approach to blood lipid management, stressing the need for public awareness and education regarding the significance of monitoring LDL-C levels [1][2] Group 2: Lifestyle and Treatment Recommendations - Lifestyle modifications, including dietary control and physical activity, are crucial as approximately two-thirds of LDL-C comes from external sources [2][3] - Regular monitoring and risk assessment of LDL-C levels are essential, especially for high-risk populations, who may require more stringent control and treatment of underlying conditions like hypertension and diabetes [2][3] Group 3: Misconceptions and Long-term Treatment - There is a prevalent misconception among patients that achieving target LDL-C levels means discontinuing medication, which can lead to adverse cardiovascular events [3][4] - Continuous and scientifically guided lipid-lowering therapy is vital for stabilizing LDL-C levels and preventing cardiovascular incidents, particularly in patients with existing ASCVD [3][4] Group 4: Current Treatment Landscape - The treatment rates and achievement rates for lipid-lowering therapy among ASCVD patients need improvement, with many still relying on traditional statin medications [4] - While statins are effective, some patients may have contraindications, necessitating the use of non-statin alternatives for optimal LDL-C management [4]